Nierenzellkarzinom: Erst Sorafenib, dann Sunitinib
Crossref DOI link: https://doi.org/10.1007/s15004-014-1005-9
Published Online: 2014-11-06
Published Print: 2014-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
red,
Text and Data Mining valid from 2014-11-01